Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2024 | Arterial Hypertension | Research

Serum PM20D1 levels in patients with idiopathic pulmonary arterial hypertension and its clinical significance

Authors: Lin Wang, Jiaxiang Liu, Liufang Zhou, Qingmei Fu

Published in: BMC Cardiovascular Disorders | Issue 1/2024

Abstract

Objective

This study aimed to investigate the serum levels of Peptidase M20 domain containing 1 (PM20D1) in idiopathic pulmonary arterial hypertension (IPAH) patients and examine its association with lipid metabolism, echocardiography, and hemodynamic parameters.

Methods

This prospective observational research enrolled 103 IPAH patients from January 2018 to January 2022. Enzyme-linked immunosorbent assay (ELISA) was used to measure the serum PM20D1 levels in all patients before treatment within 24 h of admission. Demographic data, echocardiography, hemodynamic parameters and serum biomarkers were also collected.

Results

The IPAH patients in the deceased group had significantly elevated age, right atrial (RA), mean pulmonary arterial pressure (mPAP), mean right atrial pressure (mRAP), pulmonary capillary wedge pressure (PCWP), pulmonary vascular resistance (PVR) and significantly decreased 6 min walking distance (6MWD) and tricuspid annulus peak systolic velocity (TASPV). IPAH patients showed significant decreases in serum PM20D1, low-density lipoprotein cholesterol (LDL-C), and albumin (ALB). Additionally, PM20D1 was negatively correlated with RA, NT-proBNP and positively correlated with PVR, ALB, 6MWD, and TAPSV. Moreover, PM20D1 has the potential as a biomarker for predicting IPAH patients’ prognosis. Finally, logistic regression analysis indicated that PM20D1, ALB, NT-proBNP, PVR, TASPV, RA and 6MWD were identified as risk factors for mortality in IPAH patients.

Conclusion

Our findings indicated that the serum levels of PM20D1 were significantly decreased in IPAH patients with poor prognosis. Moreover, PM20D1 was identified as a risk factor associated with mortality in IPAH patients.

Available only for authorised users

Hassoun PM. Pulmonary arterial hypertension. N Engl J Med Dec. 2021;16(25):2361–76. https://doi.org/10.1056/NEJMra2000348.CrossRef

Coons JC, Pogue K, Kolodziej AR, Hirsch GA, George MP. Pulmonary arterial hypertension: a pharmacotherapeutic update. Curr Cardiol Rep Nov. 2019;22(11):141. https://doi.org/10.1007/s11886-019-1235-4.CrossRef

Beshay S, Sahay S, Humbert M. Evaluation and management of pulmonary arterial hypertension. Respir Med. Sep 2020;171:106099. https://doi.org/10.1016/j.rmed.2020.106099.

Levine DJ. Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients. Am J Manag Care Mar. 2021;27(3 Suppl):S35–41. https://doi.org/10.37765/ajmc.2021.88609.CrossRef

Swiston JR, Johnson SR, Granton JT. Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: a systematic review of the literature. Respir Med Nov. 2010;104(11):1588–607. https://doi.org/10.1016/j.rmed.2010.08.003.CrossRef

Vazquez ZGS, Klinger JR. Guidelines for the treatment of pulmonary arterial hypertension. Lung Aug. 2020;198(4):581–96. https://doi.org/10.1007/s00408-020-00375-w.CrossRef

Agrawal V, Lahm T, Hansmann G, Hemnes AR. Molecular mechanisms of right ventricular dysfunction in pulmonary arterial hypertension: focus on the coronary vasculature, sex hormones, and glucose/lipid metabolism. Cardiovasc Diagn Ther Oct. 2020;10(5):1522–40. https://doi.org/10.21037/cdt-20-404.CrossRef

Talati M, Hemnes A. Fatty acid metabolism in pulmonary arterial hypertension: role in right ventricular dysfunction and hypertrophy. Pulm Circ Jun. 2015;5(2):269–78. https://doi.org/10.1086/681227.CrossRef

Sanchez-Mut JV, Heyn H, Silva BA, Dixsaut L, Garcia-Esparcia P, Vidal E, Sayols S, Glauser L, Monteagudo-Sánchez A, Perez-Tur J. PM20D1 is a quantitative trait locus associated with Alzheimer’s disease. Nat Med. 2018;24(5):598–603.CrossRefPubMed

10.

Li M, Gao S, Kang M, Zhang X, Lan P, Wu X, Yan X, Dang H, Zheng J. Quercitrin alleviates lipid metabolism disorder in polycystic ovary syndrome-insulin resistance by upregulating PM20D1 in the PI3K/Akt pathway. Phytomedicine Aug. 2023;117:154908. https://doi.org/10.1016/j.phymed.2023.154908.CrossRef

11.

Huang X, He P, Wu L. Clinical significance of peptidase M20 domain containing 1 ii patients with carotid atherosclerosis. Arquivos brasileiros de cardiologia. 2022;119:372–9.PubMedPubMedCentral

12.

Hou J, Chen X, Xia J, Zhang L. Down-regulation of PM20D1 is associated with clinical outcomes and prognosis of pregnant patients with diabetes mellitus. Archives Med Sci. 2022.

13.

Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J Oct. 2022;11(38):3618–731. https://doi.org/10.1093/eurheartj/ehac237.CrossRef

14.

Strange G, Lau EM, Giannoulatou E, Corrigan C, Kotlyar E, Kermeen F, Williams T, Celermajer DS, Dwyer N, Whitford H, Wrobel JP, Feenstra J, Lavender M, Whyte K, Collins N, Steele P, Proudman S, Thakkar V, Keating D, Keogh A. Survival of idiopathic pulmonary arterial hypertension patients in the modern era in Australia and New Zealand. Heart Lung Circ Nov. 2018;27(11):1368–75. https://doi.org/10.1016/j.hlc.2017.08.018.CrossRef

15.

Badagliacca R, Poscia R, Pezzuto B, Papa S, Reali M, Pesce F, Manzi G, Gianfrilli D, Ciciarello F, Sciomer S, Biondi-Zoccai G, Torre R, Fedele F, Vizza CD. Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension. J Heart Lung Transpl Oct. 2017;2. https://doi.org/10.1016/j.healun.2017.09.026.

16.

Zhang Y, Chen Y, Yao H, Lie Z, Chen G, Tan H, Zhou Y. Elevated serum circ_0068481 levels as a potential diagnostic and prognostic indicator in idiopathic pulmonary arterial hypertension. Pulm Circ Oct-Dec. 2019;9(4):2045894019888416. https://doi.org/10.1177/2045894019888416.CrossRef

17.

Hu EC, He JG, Liu ZH, Ni XH, Zheng YG, Gu Q, Zhao ZH, Xiong CM. High levels of serum lactate dehydrogenase correlate with the severity and mortality of idiopathic pulmonary arterial hypertension. Exp Ther Med Jun. 2015;9(6):2109–13. https://doi.org/10.3892/etm.2015.2376.CrossRef

18.

Xu XQ, Lv ZC, Liu QQ, Zhao QH, Wu Y, Sun K, Jiang X, Wang L, Peng FH, Jing ZC. Direct bilirubin: a new risk factor of adverse outcome in idiopathic pulmonary arterial hypertension. Int J Cardiol Feb 1. 2017;228:895–9. https://doi.org/10.1016/j.ijcard.2016.11.036.CrossRef

19.

Zhang R, Wang L, Zhao QH, Jiang R, Gong SG, Jiang X, Xu XQ, He YY, Li Y, Jing ZC. Alteration of Extracellular Superoxide dismutase in idiopathic pulmonary arterial hypertension. Front Med (Lausanne). 2020;7:509. https://doi.org/10.3389/fmed.2020.00509.CrossRefPubMed

20.

Jonas K, Waligóra M, Magoń W, Zdrojewski T, Stokwiszewski J, Płazak W, Podolec P, Kopeć G. Prognostic role of traditional cardiovascular risk factors in patients with idiopathic pulmonary arterial hypertension. Arch Med Sci Oct. 2019;15(6):1397–406. https://doi.org/10.5114/aoms.2018.79242.CrossRef

21.

Matsubara H, Ogawa A. Treatment of idiopathic/hereditary pulmonary arterial hypertension. J Cardiol Oct. 2014;64(4):243–9. https://doi.org/10.1016/j.jjcc.2014.06.009.CrossRef

22.

Li D, Liu Y, Gao W, Han J, Yuan R, Zhang M, Pang W. Inhibition of mir-324-5p increases PM20D1-mediated white and brown adipose loss and reduces body weight in juvenile mice. Eur J Pharmacol Nov. 2019;15:863:172708. https://doi.org/10.1016/j.ejphar.2019.172708.CrossRef

23.

Liu Y, Wang J, Zhou X, Cao H, Zhang X, Huang K, Li X, Yang G, Shi X. Mir-324-5p inhibits C2C12 cell differentiation and promotes intramuscular lipid deposition through lncDUM and PM20D1. Mol Ther Nucleic Acids Dec. 2020;4:22:722–32. https://doi.org/10.1016/j.omtn.2020.09.037.CrossRef

24.

Dana R, Bannay A, Bourst P, Ziegler C, Losser MR, Gibot S, Levy B, Audibert G, Ziegler O. Obesity and mortality in critically ill COVID-19 patients with respiratory failure. Int J Obes (Lond) Sep. 2021;45(9):2028–37. https://doi.org/10.1038/s41366-021-00872-9.CrossRef

25.

Karampela I, Chrysanthopoulou E, Christodoulatos GS, Dalamaga M. Is there an obesity Paradox in critical illness? Epidemiologic and metabolic considerations. Curr Obes Rep Sep. 2020;9(3):231–44. https://doi.org/10.1007/s13679-020-00394-x.CrossRef

26.

Noronha NY, Barato M, Sae-Lee C, Pinhel MAS, Watanabe LM, Pereira VAB, Rodrigues GDS, Morais DA, de Sousa WT Jr., Souza VCO, Plaça JR, Salgado W Jr., Barbosa F Jr., Plösch T, Nonino CB. Novel zinc-related differentially methylated regions in leukocytes of women with and without obesity. Front Nutr. 2022;9:785281. https://doi.org/10.3389/fnut.2022.785281.CrossRefPubMedPubMedCentral

27.

Snipelisky D, Jentzer J, Batal O, Dardari Z, Mathier M. Serum albumin concentration as an independent prognostic indicator in patients with pulmonary arterial hypertension. Clin Cardiol Jun. 2018;41(6):782–7. https://doi.org/10.1002/clc.22954.CrossRef

Title: Serum PM20D1 levels in patients with idiopathic pulmonary arterial hypertension and its clinical significance
Authors: Lin Wang
Jiaxiang Liu
Liufang Zhou
Qingmei Fu
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Arterial Hypertension
Arterial Hypertension
Published in: BMC Cardiovascular Disorders / Issue 1/2024
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-024-03855-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum PM20D1 levels in patients with idiopathic pulmonary arterial hypertension and its clinical significance

Abstract

Objective

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Serum levels of lipoprotein-associated phospholipase A2 are associated with coronary atherosclerotic plaque progression in diabetic and non-diabetic patients

Investigation of left atrial mechanical function and left ventricular systolic and diastolic parameters in athletes performing resistance exercise and combined exercise

Association between C10X polymorphism in the CARD8 gene and inflammatory markers in young healthy individuals in the LBA study

The safety and efficacy of nonvitamin K antagonist oral anticoagulants in morbidly obese patients with atrial fibrillation: a meta-analysis

A large post-stenting intramural hematoma in the left anterior descending artery caused by a small intimal calcium spur; should we respect the calcium shape?

Early and mid-term outcomes of open thoracoabdominal aortic aneurysm repair after thoracic endovascular aortic repair

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page